Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Fisher

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Annals of the Rheumatic Diseases|November 2, 2019
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapiesManuel Ramos-Casals, Pilar Brito-Zerón, Stefano Bombardieri, et al.
Clinical and Experimental Rheumatology|August 30, 2019
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Manuel Ramos-Casals, Alexandre Maria, María E Suárez-Almazor, et al.
Nature Communications|January 3, 2025
Molecular and spatial analysis of tertiary lymphoid structures in Sjogren's syndromeSaba Nayar, Jason D Turner, Saba Asam, et al.
Lancet (London, England)|February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Drugs & Aging|February 23, 2021
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's SyndromeSoledad Retamozo, Chiara Baldini, Hendrika Bootsma, et al.
The Lancet. Rheumatology|October 2, 2025
Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort studyJulien Duquesne, Louis Basseto, Charlotte Claye, et al.
Rheumatology (Oxford, England)|December 19, 2024
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional studyAlice Tison, Sandrine Jousse-Joulin, Maëlys Consigny, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
Annals of the Rheumatic Diseases|December 25, 2017
Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudyBenjamin A Fisher, Colin C Everett, John Rout, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Annals of the Rheumatic Diseases|November 2, 2019
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapiesManuel Ramos-Casals, Pilar Brito-Zerón, Stefano Bombardieri, et al.
Clinical and Experimental Rheumatology|August 30, 2019
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Manuel Ramos-Casals, Alexandre Maria, María E Suárez-Almazor, et al.
Nature Communications|January 3, 2025
Molecular and spatial analysis of tertiary lymphoid structures in Sjogren's syndromeSaba Nayar, Jason D Turner, Saba Asam, et al.
Lancet (London, England)|February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Drugs & Aging|February 23, 2021
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's SyndromeSoledad Retamozo, Chiara Baldini, Hendrika Bootsma, et al.
The Lancet. Rheumatology|October 2, 2025
Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort studyJulien Duquesne, Louis Basseto, Charlotte Claye, et al.
Rheumatology (Oxford, England)|December 19, 2024
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional studyAlice Tison, Sandrine Jousse-Joulin, Maëlys Consigny, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
Annals of the Rheumatic Diseases|December 25, 2017
Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudyBenjamin A Fisher, Colin C Everett, John Rout, et al.
Pageof 9